Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Torun
Clinical trial register · Poland

Clinical Trials in Torun, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie13 Merck Sharp & Dohme LLC11 Janssen Research & Development, LLC8 Novartis Pharmaceuticals6 Takeda5
Site location
Warsaw1315 Krakow882 Poznan705 Gdansk657 Lodz619
All 264 locations
Target enrolment
to

Trials with a site in Torun

113 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
CSL Behring
Phase 3
63
Torun, Krakow, Gliwice, Katowice, Skorzewo (Poznan)
2026-09-15
Recruiting
Takeda
Phase 3
324
Poznan, Torun, Warsaw, Chorzów, Katowice, Lodz
2026-09-10
Recruiting
Novartis Pharmaceuticals
Phase 3
188
Tarnów, Bialystok, Krakow, Lublin, Piaseczno, Torun
2026-08-04
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Gdansk, Katowice, Lublin, Skorzewo, Torun, Warsaw, Wałbrzych
2026-05-27
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Skórzewo, Torun, Wroclaw
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-22
Recruiting
Alfasigma S.p.A.
Phase 3
65
Bydgoszcz, Torun, Warsaw
2026-05-21
Recruiting
Pfizer
Phase 3
2,400
Krakow, Milówka, Bydgoszcz, Dziekanów Leśny, Poznan, Torun, Trzebnica, Wroclaw
2026-05-04
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Bydgoszcz, Krakow, Rzeszów, Szczecin, Torun, Warsaw
2026-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
140
Bydgoszcz, Torun, Lublin, Warsaw
2026-04-20
Recruiting
Takeda
Phase 3
1,182
Bialystok, Bytom, Krakow, Nowa Sól, Opole, Poznan, Sochaczew, Torun
2026-03-11
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Brzozów, Kielce, Krakow, Lodz, Lublin, Poznan, Torun, Wroclaw
2026-02-08
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Bialystok, Bydgoszcz, Elblag, Krakow, Lublin, Nadarzyn, Olsztyn, Torun
2026-01-15
Active, closed
Kailera
Phase 3
1,270
Bydgoszcz, Torun, Krakow, Lublin, Siedlce, Warsaw, Bialystok, Gdynia
2026-01-12
Recruiting
Norgine
Phase 3
212
Torun, Krakow, Warsaw, Bialystok, Gdansk, Zabrze
2025-12-29
Active, closed
Kailera
Phase 3
2,530
Poznan, Torun, Krakow, Siedlce, Warsaw, Skierniewice, Zamość
2025-12-18
Recruiting
AstraZeneca
Phase 2
320
Krakow, Torun, Warsaw, Wroclaw
2025-12-15
Active, closed
Boehringer Ingelheim
Phase 3
135
Gdansk, Torun, Warsaw
2025-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Gdansk, Torun, Warsaw
2025-11-10
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Bydgoszcz, Torun, Lublin, Warsaw, Bytom
2025-10-08
Recruiting
Lifordi Immunotherapeutics, Inc.
Phase 1
176
Torun, Warsaw
2025-10-06
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Bydgoszcz, Torun, Lublin, Warsaw
2025-09-26
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Poznan, Torun, Wroclaw, Lublin, Puławy, Warsaw, Rzeszów, Bialystok
2025-09-22
Recruiting
BeOne Medicines
Phase 3
500
Gdansk, Kielce, Lodz, Lublin, Olsztyn, Torun, Warsaw, Wroclaw
2025-09-04
Recruiting
Eli Lilly and Company
Phase 1/2
68
Katowice, Krakow, Skorzewo, Torun, Wroclaw
2025-07-30
Recruiting
Bristol-Myers Squibb
Phase 3
586
Poznan, Torun, Bialystok, Gdansk
2025-07-14
Active, closed
Incyte Corporation
Phase 3
580
Lodz, Torun, Warsaw, Wroclaw
2025-06-23
Recruiting
Pfizer
Phase 2
620
Poznan, Bydgoszcz, Torun, Puławy, Sopot, Katowice
2025-06-19
Recruiting
Seaport Therapeutics
Phase 2
360
Bełchatów, Bialystok, Bydgoszcz, Gdansk, Katowice, Leszno, Poznan, Torun
2025-06-19
Active, closed
Incyte Corporation
Phase 3
159
Gdansk, Katowice, Krakow, Lodz, Lublin, Szczecin, Torun, Warsaw
2025-06-17
Recruiting
BeOne Medicines
Phase 3
630
Lodz, Torun, Wroclaw
2025-06-11
Recruiting
Takeda
Phase 2
192
Torun, Lublin, Szczecin, Warsaw
2025-05-28
Active, closed
Sanofi
Phase 3
1,092
Bydgoszcz, Torun, Krakow, Trzebnica, Wroclaw, Warsaw, Łomianki, Siemianowice Śląskie
2025-05-22
Active, closed
Gilead Sciences
Phase 1
65
Bialystok, Gdynia, Lodz, Torun, Warszawa Targówek, Wroclaw
2025-05-14
Recruiting
Moleculin Biotech, Inc.
Phase 2/3
312
Olsztyn, Poznan, Szczecin, Torun, Warsaw
2025-03-12
Recruiting
Vanda Pharmaceuticals
Phase 3
500
Bialystok, Bydgoszcz, Gdansk, Katowice, Suchy Las, Torun
2025-03-03
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,268
Lodz, Warsaw, Częstochowa, Bydgoszcz, Kłodzko, Torun
2025-02-28
Recruiting
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NCT06590961Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.
Phase 1
94
Torun, Warsaw, Katowice, Grodzisk Wielkopolski
2025-02-20
Recruiting
GlaxoSmithKline
Phase 3
1,840
Bydgoszcz, Częstochowa, Krakow, Siemianowice Śląskie, Torun
2025-01-10
Recruiting
Boehringer Ingelheim
Phase 2
80
Krakow, Lublin, Pabianice, Poznan, Rzeszów, Sopot, Szczecin, Torun
2024-12-11
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
570
Bialystok, Bydgoszcz, Gdansk, Leszno, Torun
2024-11-21
Active, closed
Pfizer
Phase 3
600
Grudziądz, Torun, Krakow, Wroclaw, Opole, Koszalin
2024-10-21
Recruiting
argenx
Phase 3
69
Bydgoszcz, Katowice, Lodz, Lublin, Nowy Sącz, Torun
2024-10-18
Active, closed
Incyte Corporation
Phase 3
346
Gdansk, Katowice, Lodz, Lublin, Poznan, Rzeszów, Torun, Warsaw
2024-10-10
Active, closed
Eli Lilly and Company
Phase 2
143
Bydgoszcz, Krakow, Lodz, Lublin, Opole, Poznan, Sopot, Torun
2024-10-10
Recruiting
Regeneron Pharmaceuticals
Phase 2
116
Torun, Wałbrzych, Krakow, Gdansk, Lodz, Kielce
2024-09-16
Recruiting
AbbVie
Phase 2
590
Bydgoszcz, Torun, Krakow, Warsaw, Sopot, Tychy, Kielce
2024-09-04
Active, closed
AbbVie
Phase 3
699
Poznan, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice
2024-08-19
Active, closed
AbbVie
Phase 3
111
Torun, Warsaw
2024-08-08
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Łęczna, Poznan, Torun, Wroclaw, Warsaw, Rzeszów, Katowice, Szczecin
2024-08-07
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
705
Bialystok, Bydgoszcz, Gorlice, Leszno, Poznan, Torun
2024-08-05
Active, closed
Exelixis
Phase 2/3
600
Piotrków, Gliwice, Torun
2024-06-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Poznan, Bydgoszcz, Torun, Krakow, Nowy Targ, Oświęcim, Jelenia Góra, Wroclaw
2024-06-05
Recruiting
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz
Not applicable
60
Torun
2024-06-01
Recruiting
Karyopharm Therapeutics Inc
Phase 2
58
Lublin, Skórzewo, Torun
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bialystok, Bydgoszcz, Lublin, Przemyśl, Tarnów, Torun, Wieliszew, Wroclaw
2024-04-18
Active, closed
Janssen-Cilag Ltd.
Phase 3
120
Bydgoszcz, Rzeszów, Torun, Warsaw, Wroclaw, Zamość
2024-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Bialystok, Bydgoszcz, Krakow, Lublin, Przemyśl, Tarnów, Torun, Wieliszew
2024-04-09
Active, closed
Takeda
Phase 2
213
Wroclaw, Torun, Bydgoszcz, Warsaw, Szczecin, Lodz, Lublin, Rzeszów
2024-03-29
Active, closed
AbbVie
Phase 2
156
Torun, Wroclaw, Lublin, Chojnice, Tychy, Szczecin, Ksawerów
2024-03-23
Recruiting
Takeda
Phase 2
268
Torun, Wroclaw, Warsaw, Szczecin, Bydgoszcz, Lodz, Lublin, Poznan
2024-03-05
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Gdansk, Katowice, Krakow, Lodz, Torun, Warsaw, Wałbrzych
2024-02-05
Active, closed
DualityBio Inc.
Phase 3
541
Rzeszów, Torun, Krakow, Poznan, Warsaw, Wroclaw, Lodz
2024-01-18
Recruiting
Ryvu Therapeutics SA
Phase 2
98
Warsaw, Biała Podlaska, Gdansk, Katowice, Torun, Wałbrzych, Wroclaw, Zielona Góra
2024-01-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Bydgoszcz, Grudziądz, Torun, Siedlce, Koszalin, Szczecin, Kielce
2023-12-31
Recruiting
Eli Lilly and Company
Phase 3
1,264
Kielce, Szczecin, Torun
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Bydgoszcz, Grudziądz, Torun, Krakow, Warsaw, Przemyśl, Olsztyn, Lodz
2023-12-15
Recruiting
AbbVie
Phase 3
110
Torun, Warsaw
2023-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Bydgoszcz, Torun, Warsaw, Przemyśl, Gliwice, Kielce
2023-11-12
Active, closed
AbbVie
Phase 3
122
Torun, Warsaw
2023-11-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Poznan, Torun, Krakow, Nowy Targ, Wadowice, Wroclaw, Warsaw, Chorzów
2023-10-25
Recruiting
AbbVie
Phase 3
1,500
Osielsko, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice, Elblag
2023-10-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Poznan, Bydgoszcz, Torun, Chrzanów, Krakow, Tarnów, Legnica, Lublin
2023-10-09
Active, closed
AnaptysBio, Inc.
Phase 2
420
Poznan, Torun, Nowa Sól, Warsaw, Opole, Bytom, Bialystok, Bydgoszcz
2023-08-31
Active, closed
Novartis Pharmaceuticals
Phase 4
240
Krakow, Warsaw, Bydgoszcz, Sochaczew, Torun
2023-03-28
Recruiting
Grifols Therapeutics LLC
Phase 3
386
Torun, Krakow, Legnica, Wałbrzych, Słupsk, Bydgoszcz, Olsztyn
2022-12-26
Active, closed
Eli Lilly and Company
Phase 3
8,000
Gdynia, Koszalin, Lodz, Opole, Oświęcim, Siedlce, Torun, Warsaw
2022-10-04
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Bialystok, Krakow, Lodz, Rzeszów, Szczecin, Torun, Warsaw, Wroclaw
2022-09-27
Recruiting
Wroclaw Medical University
Phase 4
1,000
Bydgoszcz, Grudziądz, Torun, Chrzanów, Gorlice, Krakow, Nowy Targ, Oświęcim
2022-09-22
Recruiting
Celgene
Phase 3
810
Skórzewo, Torun, Krakow, Warsaw, Słupsk, Katowice
2022-09-20
Active, closed
Sanofi
Phase 2/3
1,856
Torun, Krakow, Tarnów, Wroclaw, Lublin, Lodz, Warsaw, Rzeszów
2022-08-22
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Bialystok, Krakow, Lublin, Nadarzyn, Olsztyn, Poznan, Torun, Warsaw
2022-06-30
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Nowy Sącz, Torun, Warsaw
2022-05-22
Recruiting
Hoffmann-La Roche
Phase 2
40
Gdansk, Torun
2022-05-12
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
293
Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Torun, Warsaw, Wroclaw
2022-04-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Konin, Poznan, Bydgoszcz, Torun, Tarnów, Siedlce, Warsaw, Przemyśl
2022-03-15
Active, closed
BeOne Medicines
Phase 3
799
Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Torun, Warsaw
2022-03-10
Recruiting
Heidelberg Pharma AG
Phase 1/2
78
Katowice, Krakow, Lodz, Opole, Skórzewo, Torun
2022-02-07
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Krakow, Rzeszów, Sosnowiec, Torun, Warsaw
2021-10-18
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Gdynia, Katowice, Krakow, Lodz, Lublin, Torun, Warsaw
2021-09-20
Active, closed
Bristol-Myers Squibb
Phase 3
338
Torun, Bydgoszcz, Elblag
2021-09-15
Active, closed
Nuvation Bio Inc.
Phase 2
217
Lodz, Poznan, Torun
2021-09-01
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bydgoszcz, Warsaw, Gdansk, Elblag, Torun, Wroclaw
2021-07-15
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Biała Podlaska, Gdansk, Katowice, Skorzewo, Torun
2021-04-09
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Skórzewo, Torun, Wroclaw, Lublin, Brzozów, Gdansk, Katowice, Wałbrzych
2021-03-11
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Lodz, Lublin, Otwock, Rzeszów, Skorzewo, Torun, Warsaw
2021-02-23
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Krakow, Wroclaw, Warsaw, Bialystok, Bydgoszcz, Poznan, Sochaczew, Torun
2020-12-22
Active, closed
AstraZeneca
Phase 1/2
702
Bydgoszcz, Gdansk, Gdynia, Grzepnica, Lodz, Torun, Warsaw
2020-11-12
Active, closed
AbbVie
Phase 3
527
Torun, Krakow, Warsaw
2020-09-30
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
240
Krakow, Torun
2020-08-20
Active, closed
AstraZeneca
Phase 3
1,012
Bydgoszcz, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Rzeszów, Torun
2020-07-13
Active, closed
Epizyme, Inc.
Phase 3
599
Skórzewo, Warsaw, Katowice, Krakow, Torun, Wroclaw
2020-06-11
Active, closed
GlaxoSmithKline
Phase 3
325
Gdansk, Krakow, Torun
2020-04-02
Active, closed
AbbVie
Phase 3
964
Bydgoszcz, Torun, Krakow, Grodzisk Mazowiecki, Warsaw, Bialystok, Elblag, Olsztyn
2019-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Poznan, Torun, Krakow, Tarnów, Wroclaw, Siedlce, Warsaw, Przemyśl
2018-12-24
Active, closed
AbbVie
Phase 3
1,242
Bydgoszcz, Torun, Krakow, Wroclaw, Warsaw, Sopot, Katowice, Tychy
2018-08-28
Active, closed
AbbVie
Phase 3
1,336
Poznan, Torun, Wroclaw, Lublin, Warsaw, Rzeszów, Chojnice, Tychy
2018-04-09
Active, closed
AbbVie
Phase 3
950
Torun, Warsaw, Sopot
2017-01-31
Active, closed
Tesaro, Inc.
Phase 1
729
Gdynia, Lublin, Olsztyn, Torun, Warsaw
2016-03-07
Active, closed
AbbVie
Phase 3
1,629
Torun, Cracow, Krakow, Wroclaw, Lublin, Grodzisk Mazowiecki, Warsaw, Bialystok
2015-12-01
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Wroclaw, Torun, Gdansk, Słupsk
2014-12-17
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Bialystok, Bydgoszcz, Gdansk, Kutno, Lodz, Poznan, Szczecin, Torun
2013-10-14
Rows per page Showing 1–113 of 113
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/torun

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 113 of those studies with a site in Torun.

How many clinical trials are recruiting in Torun?

54 of the 113 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 59 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Torun), 113 studies
PhaseStudiesRecruitingShare
Phase 3732964.6%
Phase 2241521.2%
Phase 1534.4%
Phase 4433.5%
Phase 1/2322.7%
Phase 2/3312.7%
Not applicable110.9%

Most active sponsors

Lead sponsors with the most studies (Torun)
Lead sponsorStudiesRecruiting
AbbVie133
Merck Sharp & Dohme LLC114
Janssen Research & Development, LLC85
Novartis Pharmaceuticals63
Takeda54
Bristol-Myers Squibb42
Eli Lilly and Company42
Pfizer42
AstraZeneca31
BeOne Medicines32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.